Newcomers set to nab market share in hemophilia A and B market

The hemophilia A and B market, which is set to approach $8 billion by 2026, will see a substantial number of newcomers capture market share from established companies, new research indicates.

The hemophilia market has historically been characterized by a high level of brand loyalty, noted a new report from research and consulting firm GlobalData. Companies employ huge sales forces and invest large sums in initiatives such as college scholarships, patient communities and co-pay assistance programs with the aim of creating and maintaining a life-long relationship with patients and their families.

Chiara Marchetti, healthcare analyst for GlobalData, explains: “Before the approval of long-acting factor concentrates, the movement of patients from established treatment options to new short-acting recombinant factors had been minimal due to the lack of any clinical incentive.”